FDA expands Ryaltris approval to include children aged 6 to 11 years

The FDA approved Ryaltris nasal spray for treating seasonal allergic rhinitis symptoms in children aged 6 years to less than 12 years, meaning it is now approved for patients aged 6 years and older, according to a press release.The fixed-dose combination Ryaltris (Glenmark Pharmaceuticals) nasal spray was approved for adults and children aged 12 years and older in 2022. It is made up of the

Raccontata dahealio.comthehindubusinessline.comeconomictimes.indiatimes.com